A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

January 26, 2024

Study Completion Date

January 26, 2024

Conditions
Juvenile Psoriatic ArthritisPsoriasisArthritis, Juvenile
Interventions
DRUG

Ustekinumab

This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.

Trial Locations (10)

10032

Columbia University Medical Center, New York

29425

Medical University of South Carolina, Charleston

44308

Akron Children s Hospital, Akron

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48328

Michigan Dermatology Institute, Waterford

78723

Dell Children's Medical Center of Central Texas, Austin

78757

Pediatric Rheumatology Consultants of Austin, Austin

90027

Childrens Hospital Los Angeles, Los Angeles

92648

Newport Huntington Medical Group, Huntington Beach

60611-2991

Northwestern University Feinberg School of Medicine Ann & Robert H Lurie Children's Hospital, Chicago

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY